Cheng Yin Pan Sells Shares of Prenetics Global Limited

On June 15, 2026, Cheng Yin Pan sold 15,873 shares of Prenetics Global Limited, listed on NasdaqGM under the ticker PRE. The transaction was not planned, and the shares were sold at an unspecified price. At the time, the stock was trading near $20.75.

Insider Buying and Selling at Prenetics Global Limited

Cheng Yin Pan was active on June 15, selling 15,873 shares and purchasing an equal number earlier the same day. Another insider, David Vanderveen, also made moves, buying 6,944 shares and selling 8,681 shares on the same date. Lo Hoi Chun, the Chief Financial Officer, bought 91,629 shares on May 19, 2026.

Other Institutional Activity in Prenetics Global Limited

Goldman Sachs Group Inc significantly increased its holdings in Prenetics Global Limited, adding 151,338 shares to bring its total to 193,583 shares valued at approximately $3.74 million. Millennium Management LLC also boosted its position by 141,168 shares, ending with 192,600 shares worth about $3.72 million. Wells Fargo & Company/MN made a notable increase, adding 81,806 shares to hold 84,806 shares valued at $1.64 million.

Prenetics Global Limited Stock Down 20.4%

Shares of Prenetics Global Limited (NasdaqGM: PRE) traded near $20.75. The company has a market cap of $348.7 million and a beta of 0.239, indicating lower volatility compared to the market. The stock's 52-week range is between $7.05 and $23.63, with a 50-day moving average of $18.21 and a 200-day moving average of $16.34. The company has a strong current ratio of 5.152 and a quick ratio of 4.599, with a debt-to-equity ratio of 0.378.

Recent Earnings

Prenetics Global Limited reported revenue of $120.07 million, showing a growth rate of 1.077. However, the company is not currently profitable, with a net margin of -41.99% and a return on equity of -40.77%. The next earnings report is expected on August 10, 2026.

Analysts Set New Price Targets

On June 16, 2026, Benchmark initiated coverage of Prenetics Global Limited with a 'buy' rating and a price target of $30. Lake Street also initiated coverage earlier in the year with a 'buy' rating and a $29 target. The consensus among analysts is a 'strong buy', with a mean price target of $31.25 based on four opinions.

About Prenetics Global Limited

Prenetics Global Limited is a healthcare company based in Quarry Bay, Hong Kong, focused on consumer health sciences. It develops science-backed products aimed at enhancing human health and longevity, marketed under the IM8 brand. The company also offers consumer genetic testing through its CircleDNA brand, providing personalized health reports. Prenetics was founded in 2014 and employs around 98 people, with Mr. Sheng Wu Yeung serving as CEO.

Bottom Line

Cheng Yin Pan's recent share sale at Prenetics Global Limited is part of ongoing insider activity at the company. Prenetics, trading under the ticker PRE, shows potential with a 'strong buy' consensus from analysts, despite current profitability challenges. Investors keep a close watch on such insider actions, though they reflect past decisions and not necessarily future intentions.